➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Moodys
Dow
Baxter

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMLODIPINE AND OLMESARTAN MEDOXOMIL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Amlodipine And Olmesartan Medoxomil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00185133 ↗ Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension Completed Daiichi Sankyo Inc. Phase 3 2005-05-01 This study assesses the efficacy and safety of co-administration of olmesartan medoxomil plus amlodipine in mild to severe hypertensive patients older than 18 years of age
NCT00220220 ↗ Amlodipine as Add-on to Olmesartan in Hypertension Completed Sankyo Pharma Gmbh Phase 3 2005-04-01 Test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with olmesartan alone.
NCT00220233 ↗ Olmesartan as an Add-on to Amlodipine in Hypertension Completed Sankyo Pharma Gmbh Phase 3 2005-04-01 This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone
NCT00311155 ↗ Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension Completed Sankyo Pharma Gmbh Phase 4 2006-03-01 This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00649389 ↗ Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension Completed Daiichi Sankyo Inc. Phase 3 2008-05-01 To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00654745 ↗ 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics Completed Daiichi Sankyo Inc. Phase 4 2008-05-01 To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
NCT00791258 ↗ A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure Completed Integrium Phase 4 2008-11-01 The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amlodipine And Olmesartan Medoxomil

Condition Name

Condition Name for Amlodipine And Olmesartan Medoxomil
Intervention Trials
Hypertension 6
Essential Hypertension 6
Healthy Subjects 2
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amlodipine And Olmesartan Medoxomil
Intervention Trials
Hypertension 10
Metabolic Syndrome X 1
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amlodipine And Olmesartan Medoxomil

Trials by Country

Trials by Country for Amlodipine And Olmesartan Medoxomil
Location Trials
United States 122
Germany 5
Philippines 3
Belgium 2
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amlodipine And Olmesartan Medoxomil
Location Trials
Virginia 4
North Carolina 4
Texas 4
Florida 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amlodipine And Olmesartan Medoxomil

Clinical Trial Phase

Clinical Trial Phase for Amlodipine And Olmesartan Medoxomil
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amlodipine And Olmesartan Medoxomil
Clinical Trial Phase Trials
Completed 13
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amlodipine And Olmesartan Medoxomil

Sponsor Name

Sponsor Name for Amlodipine And Olmesartan Medoxomil
Sponsor Trials
Daiichi Sankyo Inc. 6
Sankyo Pharma Gmbh 3
Torrent Pharmaceuticals Limited 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amlodipine And Olmesartan Medoxomil
Sponsor Trials
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Baxter
Merck
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.